Pandemics are no stranger to Lovelace Biomedical. We have previously worked on studies to find vaccines for SARS and other Coronavirus strains. Now, with COVID-19 needing a cure, we have mobilized our teams to start aiding in the fight against SARS-CoV-2 (the virus that causes COVID-19), as we did for the 2003 SARS virus
Lovelace is leveraging its past experience with SARS-CoV1 to rapidly engage key resources (bio containment facilities, personnel, commercial and academic partners, etc) to support SARS-CoV2 research and drug development efforts
Understanding the pathogenesis of COVID19 in an ever changing environment and then translating that into effective models/tools that can be reliably used for testing therapeutics and vaccines does not happen overnight. This effort requires the integration of existing resources that are refocused to address the present situation and the development of new resources
Lovelace has been able to maintain and operate ABSL3 facilities through collaborations with government and commercial sponsors
Lovelace has engaged multiple partners from both government and commercial sectors to develop reliable preclinical resources to expedite the development of novel therapeutics and vaccine targeting COVID19
See the FDA guidance here where Lovelace Biomedical’s scientists have contributed
18 For general information, see Tepper, J. S., et al., 2016, Symposium Summary: “Breathe In, Breathe Out, It’s Easy: What You Need to Know About Developing Inhaled Drugs,” Int J Toxicol, 35(4): 376–392.
We have a program in place, and our team is ready to deploy your studies for development in animal models used to evaluate medical countermeasures for SARS-Co V-2
Primary Severe Acute Respiratory Syndrome Coronavirus Infection Limits Replication but Not Lung Inflammation upon Homologous Rechallenge
Severe acute respiratory syndrome-coronavirus infection in aged nonhuman primates is associated with modulated pulmonary and systemic immune responses
Lovelace Biomedical is a globally recognized leader in treatment and regulation against infectious diseases. Our team conducts a full range of infectious disease studies under both Good Laboratory Practice (GLP) or non-GLP guidelines. We have the capability of exploring a variety of infectious diseases with our ABSL 1, 2, 3 & 3+ facilities. We integrate quality, leading-edge expertise, and an experienced and well trained staff to meet study goals.
Lovelace Biomedical is one of only a handful of commercially focused, non-governmental and non-academic ABSL-3 labs in the United States.
With the current state of the health crisis the world is facing in Covid-19, (SARS-CoV-2 Coronavirus), we are well equipped and able to host studies using our ABSL-3 labs to study your compounds. We specialize in these highly contagious and dangerous viral studies. Our extensive research history on deadly and dangerous diseases includes many other other Viral, bacterial, and fungal models, such as Zika, Anthrax and Crytpococcus.
Lovelace Biomedical has over 10,000 square feet of ABSL3-enhanced laboratory space, with six multi-species animal rooms capable of housing rodents, rabbits, ferrets and non-human primates. The high-containment labs are fully GLP compliant with remote telemetry capabilities, two aerosol exposure laboratories, a state-of-the art necropsy suite with full hematology and clinical chemistry analysis capabilities, as well as fully equipped microbiology and virology laboratories.